<DOC>
	<DOCNO>NCT01986920</DOCNO>
	<brief_summary>Evaluate safety , tolerability A-101 apply seborrheic keratosis lesion back subject .</brief_summary>
	<brief_title>Study Safety , Tolerability Effectiveness A-101 Subjects With Seborrheic Keratosis</brief_title>
	<detailed_description>The main objective study evaluate safety , effectiveness tolerability three concentration A-101 25 % , 32.5 % , 40 % , apply individual seborrheic keratosis target lesion back compare match A-101 vehicle .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Keratosis , Seborrheic</mesh_term>
	<criteria>1 . Is least 18 year age 2 . Has clinical diagnosis stable clinically typical seborrheic keratosis 3 . Has least 4 appropriate seborrheic keratosis target lesion back 4 . If subject woman childbearing potential , must negative urine pregnancy test must agree use active form birth control duration study 5 . Is nonpregnant nonlactating 6 . Is good general health free disease state physical condition , investigator 's opinion , might impair evaluation target lesion expose subject unacceptable risk study participation 7 . Is willing able follow study instruction attend study visit 8 . Is able comprehend willing sign Informed Consent Form ( ICF ) . 1 . Has clinically atypical and/or rapidly grow seborrheic keratosis lesion 2 . Has presence multiple eruptive seborrheic keratosis lesion ( Sign LesserTrelat ) 3 . Has use follow systemic therapy within specified period prior Visit 1 : Retinoids ; 180 day Glucocorticosteroids ; 28 day Antimetabolites ( e.g. , methotrexate ) ; 28 day 4 . Has use follow topical therapy treatment area within specified period prior Visit 1 : Retinoids ; 90 day Liquid nitrogen , electrodessication , curettage , imiquimod , 5flurouracil , ingenol mebutate ; 60 day Glucocorticosteroids antibiotic ; 14 day Moisturizers/emollients , sunscreens ; 12 hour 5 . Has LASER , light ( e.g. , intense pulse light [ IPL ] , photodynamic therapy [ PDT ] ) energy base therapy treatment area within 180 day prior Visit 1 6 . Has history keloid formation hypertrophic scar 7 . Has current systemic malignancy 8 . Has history , within 180 day prior Visit 1 , current cutaneous malignancy treatment area 9 . Has current premalignancy ( e.g. , actinic keratosis ) treatment area 10 . Has body art ( e.g. , tattoo , piercing , sculpt , etc . ) invasive , nontherapeutic procedure perform treatment area , opinion investigator , might put subject undue risk interfere study conduct evaluation 11 . Has excessive tan treatment area , opinion investigator , might put subject undue risk interfere study conduct evaluation 12 . Has experience sunburn treatment area within previous 4 week 13 . Has history sensitivity ingredient study medication 14 . Has current skin disease ( e.g. , psoriasis , atopic dermatitis , eczema , sun damage , etc . ) , condition ( e.g. , sunburn , tattoo , excessive hair , open wound back ) , opinion investigator , might put subject undue risk interfere study conduct evaluation 15 . Has participate investigational drug trial administration investigational study medication occur within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>SK</keyword>
</DOC>